Gan & Lee Pharmaceuticals. (603087.SS)
- Previous Close
48.00 - Open
47.80 - Bid 48.77 x --
- Ask 48.78 x --
- Day's Range
47.79 - 49.31 - 52 Week Range
32.10 - 62.90 - Volume
15,904,276 - Avg. Volume
11,872,264 - Market Cap (intraday)
28.977B - Beta (5Y Monthly) --
- PE Ratio (TTM)
113.42 - EPS (TTM)
0.43 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 20, 2022
- 1y Target Est
62.00
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. The company's products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro and lispro mix 75/25 injection; Prandilin 25, an insulin lispro injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection. It also offers GanleePen, an insulin injection device; GanleeFine, an insulin pen needle; and medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.
www.ganlee.comRelated News
Performance Overview: 603087.SS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 603087.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 603087.SS
Valuation Measures
Market Cap
28.98B
Enterprise Value
24.83B
Trailing P/E
113.42
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.66
Price/Book (mrq)
2.93
Enterprise Value/Revenue
10.43
Enterprise Value/EBITDA
590.31
Financial Highlights
Profitability and Income Statement
Profit Margin
14.82%
Return on Assets (ttm)
1.32%
Return on Equity (ttm)
3.78%
Revenue (ttm)
2.61B
Net Income Avi to Common (ttm)
386.85M
Diluted EPS (ttm)
0.43
Balance Sheet and Cash Flow
Total Cash (mrq)
4.9B
Total Debt/Equity (mrq)
0.06%
Levered Free Cash Flow (ttm)
-515.11M
Research Analysis: 603087.SS
Company Insights: 603087.SS
603087.SS does not have Company Insights